Biotech Scorecard: My Best and Worst Calls

It's report card time. I've been going over a year's worth of biotech columns to grade my hits and misses for 2008.

My best call this year was more directional than stock-specific. In mid-February, I reported how the empty rooms and lack of investor interest at the BIO CEO investor conference was a red flag for small-cap biotech stock investing in 2008.

As I stated at the time:

"The reasons are fairly obvious: A nasty stock market and looming threat of recession has put investors in a foul mood. In this atmosphere, risk is most definitely a four-letter word, so there are few institutional investors willing to take on even more by loading up on risky small- and mid-cap biotech stocks."

...